We're looking forward to attending the BIO International Convention later this month and connecting with colleagues, partners, and innovators from across the global life sciences community. Join Dr. Sabeen Mekan, Zymeworks' Chief Medical Officer, for the panel discussion "The Next Generation of ADCs: Building Kinder, Gentler Cancer Therapeutics" on June 25 at 10:15–11:15 am PT. We’ll also be delivering a company presentation highlighting Zymeworks' approach to developing novel antibody-based therapeutics on June 24 at 3:45 pm PT. Members of our Business Development and leadership teams will be onsite throughout the conference and available to connect. We look forward to discussing our science and partnership opportunities. See you at #BIO2026! #ADCs #TCellEngagers #BusinessDevelopment

We’re pleased to share that Dr. Sabeen Mekan will be participating in the CMO Summit panel discussion, “Existing Pipelines: Maintaining Clinical Progress” on June 16 at 8:30 am ET. The session will explore evolving regulatory considerations shaping the future of biotech innovation and drug development. Learn more: longwoodhealthcareleaders.co…

Today, on National Cancer Survivors Day, we recognize and celebrate the strength, resilience, and journeys of cancer survivors everywhere. At Zymeworks, patients remain at the center of everything we do. We are inspired by the courage of survivors and remain committed to advancing innovative therapies that aim to improve outcomes for people living with difficult to treat diseases. Learn about our programs: zymeworks.com/pipeline/ #CancerSurvivorsDay #Oncology

We’re excited to participate in the World Bispecific Summit in South Korea next week. Dr. Alexey Berezhnoy, Zymeworks' Senior Director of Immunology, will present “ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation” and share insights into our continued work advancing next-generation multispecific therapeutics. View the conference program:worldbispecifics-tce-kr.com/ #COPD #bispecifics

We’re looking forward to participating in the Jefferies Global Healthcare Conference in New York this week. Management will take part in a fireside chat on June 3 at 8:45 a.m. ET to discuss our continued progress advancing innovative therapeutics for patients with difficult-to-treat cancers and other serious diseases. Join the webcast here: event.summitcast.com/view/SS…

Happy #PrideMonth! This month, we recognize and celebrate the history and contributions of the #LGBTQ community and the ongoing pursuit of equality, inclusion, and acceptance. At Zymeworks, we believe that different perspectives, experiences, identities, and backgrounds make us stronger. We are committed to fostering a culture where employees feel supported, valued, and empowered to bring their authentic selves to work. We’re proud to celebrate Pride and amplify the voices of the LGBTQ community across the life sciences industry. #Pride2026 #Biotech

This Memorial Day, we honor and remember the courageous individuals who gave their lives in service to their country. Their sacrifice serves as a lasting reminder of the freedoms we value and the responsibility we share to uphold them. At Zymeworks, we are grateful to those who served and to the families who continue to carry their legacy forward. Wishing everyone a meaningful Memorial Day.

We’re looking forward to participating in the @Stifel Virtual Targeted Oncology Forum this week. Management will take part in a fireside chat on May 20 at 9:00 am ET - join the webcast: event.summitcast.com/view/SS…

We just wrapped a great week at PEGS Boston and appreciated the opportunity to connect with so many colleagues advancing the field of antibody engineering. Our team was proud to share some of our latest work — thank you to everyone who stopped by to connect! If you missed the presentations or want to revisit the data, access the presentations here: zymeworks.com/publications/ Curious about our ADC and multispecific programs? Learn more at zymeworks.com/innovation/ #ADC #antibodydrugconjugate #trispecifics #PEGSBoston

We’re pleased to welcome Paul Schneider as our new General Counsel. With more than 20 years of legal experience advising on strategic transactions across the life sciences sector – including in-licensing, out-licensing, collaborations, and M&A – his combination of legal expertise and scientific background will be valuable as we continue advancing our pipeline and business. We also extend our sincere thanks to our outgoing General Counsel, Daniel Dex, for his contributions over the past several years. Since joining Zymeworks in 2017, he has played an important role in helping shape the company and has been a trusted advisor to leadership. We are grateful for his impact and wish him all the best in his next chapter.

Management are pleased to present at the following investors conferences in May and June - learn more: ir.zymeworks.com/news-releas…

We’re heading to the 2026 Respiratory Innovation Summit in Orlando, FL (May 15–16), hosted by the American Thoracic Society! Our team will present “ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD” (poster no. 117), showcasing our work on our novel IL-4Rɑ x IL-33 bispecific molecule targeting respiratory inflammation, including mixed-type chronic obstructive pulmonary disease (COPD). Stop by to connect with our team and learn more about our AIID programs. Learn more: zymeworks.com/zymeworks-to-p… #RespiratoryInnovation #COPD #Bispecific #AIID

Ovarian cancer remains one of the most challenging cancers to diagnose and treat — with many patients facing limited options, especially in later stages. Advancing new approaches is critical to changing this reality. On World Ovarian Cancer Day, we recognize the urgency of continued research and innovation — and the importance of working toward better outcomes for patients. #WorldOvarianCancerDay #OvarianCancer #OncologyResearch #OvarianCancerAwareness

Today we reported our Q1 2026 financial results. Join our management team for a live webcast at 4:30 pm ET as we review business updates and progress across our pipeline. Join the webcast: edge.media-server.com/mmc/p/… Read the press release: ir.zymeworks.com/news-releas…

We’re heading to PEGS Boston next week! Join us for: Panel Advancing Multispecific Antibodies and Combination Therapies to the Clinic May 13 | 2:40 pm ET Presenter: Dr. Nina E. Weisser Posters Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADC May 12 | 4:00 pm ET May 13 | 6:20 pm ET Presenter: Dr. Germanna Righetto TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation May 14 | 8:50 am ET Presenter: Dr. Genevieve Desjardins If you’re attending, we’d welcome the opportunity to connect. Learn more about our ADC and multispecific programs: zymeworks.com/antibody-scien… #PEGSBoston #ADC #Multispecifics #Biotech

May is National Cancer Research Month. Our mission is rooted in advancing science that makes a meaningful difference for patients with difficult to treat cancers. Through our fully integrated, in-house R&D engine, we’re working to translate innovative science into potential new treatment options. To the researchers, clinicians, and patients driving progress forward — we’re proud to be part of this effort. Learn more: zymeworks.com/innovation/ #CancerResearch #Biotech #Innovation #Oncology

May is Mental Health Awareness Month — a reminder that taking care of our mental well-being is just as important as physical health. At Zymeworks, we’re committed to fostering a workplace where our people feel supported, balanced, and empowered to do their best work — for themselves and for the patients we serve. Our Health & Wellness benefits programs, such as ZymeLife and Flexible Time-off, are designed to support employees in prioritizing their well-being. Learn more: zymeworks.com/careers/ #MentalHealthAwarenessMonth #MentalHealthAtWork

Congratulations to the team at @BeOneMedicines on this important milestone! The FDA’s Priority Review highlights the potential of this combination approach in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma—an area with significant unmet need for patients. #GEA #oncology

We’re pleased to share news from our partner, @JazzPharma! Backed by Phase 3 data, this sBLA highlights an important step forward to redefine care for people living with HER2 gastroesophageal adenocarcinoma, where significant unmet need remains.